Because a big part of managing your multiple sclerosis (MS) is properly treating it, you may find it helpful to understand what clinical trials are and how they work. A clinical trial is a research study used to determine if a certain treatment is safe and effective. It’s a way for the Food and Drug Administration (FDA) to determine if a treatment should be approved for doctors to legally prescribe to patients.
Clinical trials are part of a lengthy research process. This process usually begins in a lab on a cellular level and then moves to testing on animals. If the research appears to have potential, clinical trials may be set up to see how the treatment being researched would work on a person. If the treatment is approved, the outcome of the clinical trial is one piece of information your doctor may use when recommending treatment options.
It typically takes 10 to 15 years for an experimental drug to get approved for use in patients.
Clinical trials are meant to determine how safe and effective a treatment may be for patients. To help determine this, researchers and manufacturers will work together to develop the study's objectives, design, and methods—also known as a protocol. Some of the ways a research group may choose to design a study are:
By breaking the participants into groups, researchers can compare treatments with one another or compare a treatment with a placebo. The two main groups participants are usually placed in are:
Enrolling individuals with certain conditions or symptoms is an important part of the clinical trial process. This allows researchers to determine if the treatment may work in a specific population. Every trial develops unique guidelines that determine which patients are able to participate based on a number of different criteria specific to that trial. Criteria may include a certain age range, gender, symptom, or illness. And the number of participants can change based on the disease state or condition.
New treatments go through three phases of research before they can be approved by the FDA and become available to the public. Each phase is designed to answer a separate research question. This is usually determined in the protocol. Knowing the phase of the clinical trial is important because it can give an idea about how much is known about the treatment being studied.
In phase 1, the goal is to find out how a treatment will interact with the body. Researchers test a new treatment in a small group of healthy people to evaluate how safe it is, determine how much should be given, and identify possible side effects.
Average length of study: Several months
In phase 2, the goal is to gather data on whether the treatment works in people with a certain disease or condition. The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety. During this phase, different doses of a drug may be studied to determine the safest and most effective dose.
Average length of study: Several months to two years
The goal is to gather more information about safety and demonstrate whether or not a treatment can be beneficial to a specific population. The treatment is given to a larger group of people than in previous phases to determine its benefits, identify side effects, compare it with other treatments, and see how the treatment can be used appropriately.
Average length of study: One to four years
The main objective of a clinical trial is to produce results for something called a primary endpoint. This is the key piece of information the trial was designed to measure. In MS, two commonly measured endpoints are:
Clinical trials can be a way to research new treatments. They not only provide the basis for the development and marketing of new treatments, but also help develop other products and devices.
Because Biogen is committed to helping to advance science, we are continuously doing research on new treatments for MS.